MapLight Therapeutics shows weak fundamental quality, extreme insider selling, and a streak of earnings misses, though an overbought bounce shows some near-term buying interest.
Thesis pillars
- Earnings Miss Streak↑Improving
- Weak Fundamental Quality→Stable
- Extreme Insider Selling→Stable
- +1 more pillar — see the Why tab for full reasoning
MapLight Therapeutics, Inc. (MPLT) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $36.56: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Elevated put/call ratio: 10.75; Below-average business quality.
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing circuit-specific drugs for central nervous system disorders, using a discovery platform that links neural circuit activity to disease behaviors. Its lead candidate, ML-007C-MA, a fixed-dose muscarinic... Read more
Sell if holding. Engine safety override at $36.56: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Elevated put/call ratio: 10.75; Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 4.5/10, moderate confidence.
Passes 4/8 gates (news boost analyst 0.70, earnings proximity 18d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and clean insider activity. Suitability: speculative.
About MapLight Therapeutics, Inc.
About MapLight Therapeutics, Inc.
MapLight Therapeutics has no products approved for commercial sale and reported a net loss of $161.2 million for 2025, widening from $77.6 million in 2024, as it advances ML-007C-MA, a fixed-dose muscarinic agonist combined with a peripheral anticholinergic, through Phase 2 trials for schizophrenia (ZEPHYR) and Alzheimer's disease psychosis (VISTA). The FDA granted the program Fast Track designation in December 2025 for treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. The company's accumulated deficit reached $360.5 million as of December 31, 2025.
MapLight generates no product revenue and instead funds research and development, manufacturing and clinical trial costs through equity issuances, with substantially all of its losses tied to platform development, clinical trials and general administrative costs. Its lead program, ML-007C-MA, targets M1 and M4 muscarinic receptors in the brain while pairing the agonist with a peripherally acting anticholinergic designed to limit the procholinergic side effects that have limited rival muscarinic drugs such as Bristol Myers Squibb's Cobenfy (xanomeline-trospium). The company also advances ML-004, a 5-HT1B/1D agonist in a Phase 2 trial for autism spectrum disorder, and several earlier-stage discovery programs (ML-009, ML-055, ML-021) built on its optogenetics, single-cell transcriptomics and STARmap discovery platform developed with the University of Edinburgh. Because none of these programs have generated revenue, spending is expected to increase substantially as trials advance toward regulatory filings.
Show full overview
MapLight's near-term value is concentrated in a single dosing regimen of ML-007C-MA across two indications: the ZEPHYR trial is expected to reach its 300-participant enrollment target in April 2026 with topline results in the third quarter of 2026, while the VISTA trial in Alzheimer's disease psychosis is not expected to report until the second half of 2027. A negative readout in either trial, given that both rely on the same fixed-dose combination and CSF exposure target established in the company's Phase 1 Study 013, could simultaneously undermine both indications rather than isolate the setback to one program.
See also: Healthcare · Biotechnology
From MapLight Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-26Recent Developments — MapLight Therapeutics, Inc.
Latest news
- NEWS Maplight Therapeutics Says Phase 2 Zephyr Trial Of ML-007C-MA For Acute Exacerbation Of Schizophrenia Met Its Primary En — benzinga Jul 27, 2026 positive
- NEWS UBS Maintains Buy on MapLight Therapeutics, Raises Price Target to $52 — benzinga Jul 21, 2026 positive
- NEWS BMO Capital Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $46 — benzinga Jul 21, 2026 positive
- NEWS Needham Maintains Buy on MapLight Therapeutics, Raises Price Target to $45 — benzinga Jul 10, 2026 positive
Generated 2026-07-27T12:08:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineML-007C-MA (lead product candidate)10-K Item 1: 'Our lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic'
Material Events(8-K, last 90d)
- 2026-06-18Item 5.02MEDIUMCFO Vishwas Setia separated effective June 18, 2026 following a human-resources violation review, unrelated to financial or clinical matters. Jonathan Gillis, the company's Chief Administrative and Accounting Officer, was appointed interim CFO effective immediately. No severance paid to Setia.SEC filing →
- 2026-04-29Item 5.02LOWDirectors Robert Malenka and Jim Trenkle will not stand for reelection at the June 23, 2026 annual meeting; decisions were not due to any disagreement with the company. Board nominated Martin Babler and Troy Cox as replacement Class I director nominees.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.6% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $36.56: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Elevated put/call ratio: 10.75; Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $34.00. Score 4.5/10, moderate confidence.
Take-profit target: $38.15 (+4.3% upside). Prior stop was $34.00. Stop-loss: $34.00.
Concentration risk — Pipeline: ML-007C-MA (lead product candidate); Quality below floor (1.6 < 4.0).
MapLight Therapeutics, Inc. trades at a P/E of N/A (forward -9.6). TrendMatrix value score: 5.0/10. Verdict: Sell.
18 analysts cover MPLT with a consensus score of 4.3/5. Average price target: $44.
What does MapLight Therapeutics, Inc. do?MapLight Therapeutics is a clinical-stage biopharmaceutical company developing circuit-specific drugs for central...
MapLight Therapeutics is a clinical-stage biopharmaceutical company developing circuit-specific drugs for central nervous system disorders, using a discovery platform that links neural circuit activity to disease behaviors. Its lead candidate, ML-007C-MA, a fixed-dose muscarinic agonist/antagonist combination, is in Phase 2 trials (ZEPHYR and VISTA) for schizophrenia and Alzheimer's disease psychosis and received FDA Fast Track designation in December 2025. The company has no approved products and funds development through equity financing, reporting a $161.2 million net loss and $360.5 millio